Page last updated: 2024-08-21

oxazoles and Local Neoplasm Recurrence

oxazoles has been researched along with Local Neoplasm Recurrence in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (33.33)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (16.67)	24.3611
2020's	3 (50.00)	2.80

Authors

Authors	Studies
Ballman, KV; Blinder, V; Borges, VF; Carey, LA; Goetz, MP; Irvin, WJ; Kommalapati, A; Krop, I; Lee, M; McCall, L; Mitchell, M; O'Sullivan, CC; Partridge, AH; Symmans, WF; Tung, NM; Weiss, A; Zemla, T	1
Chen, X; Ding, W; Jiang, L; Liu, A; Liu, J; Shi, X; Wen, C; Zhang, H; Zhou, H	1
Gelmon, KA; Tesch, ME	1
Ahmed, A; Atula, T; Haglund, C; Hagström, J; Lehtonen, S; Mäkinen, LK; Mäkitie, AA; Salo, T	1
Ansbacher, R	1
Carbone, PP; Davis, TE; Earle, JD; Elson, PJ; Glover, DJ; Hahn, RG; Kvols, LK; Trump, DL; Vogl, SE	1

Reviews

1 review(s) available for oxazoles and Local Neoplasm Recurrence

Article	Year
Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. Drugs, 2020, Volume: 80, Issue:17 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab	2020

Article

Year

Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.

Drugs, 2020, Volume: 80, Issue:17

Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast; Breast Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunoconjugates; Lapatinib; Mastectomy; Maytansine; Medical Oncology; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxazoles; Practice Guidelines as Topic; Pyridines; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab

2020

Trials

1 trial(s) available for oxazoles and Local Neoplasm Recurrence

Article	Year
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future oncology (London, England), 2021, Volume: 17, Issue:34 Topics: Ado-Trastuzumab Emtansine; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxazoles; Placebos; Prospective Studies; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2	2021

Article

Year

Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

Future oncology (London, England), 2021, Volume: 17, Issue:34

Topics: Ado-Trastuzumab Emtansine; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Oxazoles; Placebos; Prospective Studies; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2

2021

Other Studies

4 other study(ies) available for oxazoles and Local Neoplasm Recurrence

Article	Year
Cyclin-dependent kinase 7/9 inhibitor SNS-032 induces apoptosis in diffuse large B-cell lymphoma cells. Cancer biology & therapy, 2022, 12-31, Volume: 23, Issue:1 Topics: Animals; Apoptosis; Cyclin-Dependent Kinases; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Nude; Neoplasm Recurrence, Local; Oxazoles; Thiazoles	2022
Toll-like receptors 2, 4, and 9 in primary, metastasized, and recurrent oral tongue squamous cell carcinomas. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2016, Volume: 45, Issue:5 Topics: Acetates; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Line, Tumor; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxazoles; Squamous Cell Carcinoma of Head and Neck; Toll-Like Receptor 2; Toll-Like Receptor 4; Toll-Like Receptor 9; Toll-Like Receptors; Tongue Neoplasms	2016
Treatment of endometriosis with Danazol. American journal of obstetrics and gynecology, 1975, Jan-15, Volume: 121, Issue:2 Topics: Adult; Castration; Endometriosis; Ethisterone; Fallopian Tubes; Female; Humans; Hysterectomy; Isoxazoles; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Oxazoles; Uterine Neoplasms	1975
Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Investigational new drugs, 1988, Volume: 6, Issue:2 Topics: Adult; Aged; Alanine; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Evaluation; Female; Humans; Isoxazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxazoles; Thiadiazoles; Vinblastine	1988